Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Opinion|Videos|February 14, 2025 (Updated: January 31, 2025)
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
This segment explores Dr. Rossi's clinical experience with cilta-cel as a second-line therapy, focusing on its efficacy and quality-of-life benefits across diverse patient populations.
Advertisement
Video content above is prompted by the following:
- Can you share your experience with cilta-cel as a second-line therapy?
- What advantages in terms of efficacy and quality of life have you noted across various patient populations?
Advertisement
Related to this article
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
Adjuvant Ribociclib Improves OS at 6 Years in HR+/HER2- Early Breast Cancer
3
Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC
4
Extended Letrozole Sustains DFS Benefit at 15 Years in HR+ Breast Cancer
5